




A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions


Washington State Transactions by Sector

Transaction Amounts per Year



Number of Deals per Sector

*As of 1/8/2020



Monthly Highlights

HIGHLIGHTS

- **Silverback Therapeutics** raised \$241M in the second WA-state biotech IPO of 2020 (following Athira Pharma in October 2020). ImmunoTAC, a proprietary software platform, develops therapies that target specific areas of disease without damage to healthy tissue. Silverback’s lead product candidate, SBT6050, uses monoclonal antibodies to target breast, gastric, and lung cancers. ([Geekwire](#); [Silverback Therapeutics](#))
- **Athira Pharma** was awarded \$15M grant from National Institute on Aging (NIA) to support a clinical trial of a treatment that aims to stop deterioration of neurons and restore healthy brain activity in patients with mild to moderate cases of Alzheimer’s disease. ([Geekwire](#); [Athira Pharma](#))
- **Freespira** raised \$10M for its product that includes software to coach people using breathing techniques and a CO2 monitor. **Freespira** has FDA approval for treating panic disorder and PTSD. Its headquarters are in Kirkland, WA. ([Geekwire](#); [Freespira](#))
- The FDA issued Emergency Use Authorization for **two COVID-19 vaccines**, the first from Pfizer and the second from Moderna. ([US Food & Drug Administration](#))
- The **Bill & Melinda Gates Foundation** committed an additional \$250M to support research, development, and equitable delivery of lifesaving tools. ([Gates Foundation Press Release](#))

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact laura@lswinstitute.org.

**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.



Washington Life Science Transactions

| Date | Company | Type | Amount | Location | Date | Company | Type | Amount | Location |
|-----------|-------------------------------|--------------------------|---------------|---------------|-----------|-------------------------|------------------|---------------|-------------------|
| 1/20/2020 | Optimize.health | Equity | \$3,500,000 | Seattle | 5/12/2020 | Lengo Therapeutics | Equity | \$15,000,000 | Seattle |
| 1/22/2020 | 3x4 Genetics | Equity | \$550,000 | Bellevue | 5/13/2020 | Solius | Equity | \$12,000,000 | Bainbridge Island |
| 1/23/2020 | Athira Pharma | Convertible Debt | \$3,830,000 | Seattle | 5/18/2020 | Nautilus Biotechnology | Equity | \$76,060,000 | Seattle |
| 1/29/2020 | Ventec Life Systems | Equity | \$24,030,000 | Seattle | 5/21/2020 | Good Therapeutics | Equity | \$22,340,000 | Seattle |
| 1/31/2020 | Twistle | Equity | \$18,000,000 | Seattle | 5/22/2020 | MDMetrix | Convertible Note | \$1,150,000 | Seattle |
| 1/31/2020 | Soovu Labs | Convertible Debt | \$800,000 | Seattle | 5/22/2020 | Stratos Genomics | M&A | undisclosed | Seattle |
| 2/1/2020 | ActX | Equity | \$5,900,000 | Seattle | 5/22/2020 | Tasso | Equity | \$17,000,000 | Seattle |
| 2/1/2020 | Inmedix | Equity | undisclosed | Normandy Park | 5/27/2020 | Alvaxa Biosciences | M&A | undisclosed | Seattle |
| 2/11/2020 | Cardiac Insight | Debt | \$8,000,000 | Bellevue | 6/2/2020 | eDoula | Convertible Debt | \$50,000 | Mercer Island |
| 2/14/2020 | Bardy Diagnostics | Equity | \$12,490,000 | Seattle | 6/4/2020 | Kineta | Equity | \$100,000 | Seattle |
| 2/18/2020 | PharmID | Equity | \$5,000,000 | Seattle | 6/4/2020 | Athira Pharma | Equity | \$85,500,000 | Seattle |
| 2/19/2020 | CuraCloud | Equity | undisclosed | Seattle | 6/10/2020 | MacroHealth | Equity | \$54,000,000 | Kirkland |
| 2/20/2020 | Lupa Bio | Convertible Debt | undisclosed | Seattle | 6/11/2020 | Sana Biotechnology | Equity | \$435,000,000 | Seattle |
| 2/21/2020 | AVM Biotechnology | Equity | \$2,570,000 | Seattle | 6/12/2020 | MicrobiomX | Convertible Debt | \$505,000 | Seattle |
| 2/24/2020 | Selkirk Pharma | Equity | \$9,050,000 | Spokane | 6/17/2020 | Proprio | Equity | \$23,000,000 | Seattle |
| 2/25/2020 | Oisin Biotechnologies | Equity | \$2,970,000 | Seattle | 6/22/2020 | Oisin Biotechnologies | Equity | \$5,090,000 | Seattle |
| 2/26/2020 | PVP Biologics | M&A | \$330,000,000 | Seattle | 6/24/2020 | Cajal Neuroscience | Equity | \$65,700,000 | Seattle |
| 2/27/2020 | WellPepper | Equity | undisclosed | Seattle | 6/24/2020 | Modento | Equity | \$1,000,000 | Issaquah |
| 3/1/2020 | Joylux | Equity | undisclosed | Seattle | 7/8/2020 | LumniThera | Equity | \$14,000,000 | Poulsbo |
| 3/1/2020 | LumniThera | Equity | undisclosed | Poulsbo | 7/13/2020 | Ulcer Solutions | Equity | undisclosed | Ridgefield |
| 3/1/2020 | Nanodropper | Equity | \$30,000 | Seattle | 7/13/2020 | Medcurity | Equity | \$1,200,000 | Spokane |
| 3/4/2020 | Pathware | Convertible Debt | \$2,500,000 | Seattle | 7/13/2020 | Innovega | Equity | \$2,140,000 | Bellevue |
| 3/11/2020 | Silverback Therapeutics | Equity | \$78,500,000 | Seattle | 7/21/2020 | Revalerio | Equity | \$26,370,000 | Tacoma |
| 3/11/2020 | OtoNexus Medical Technologies | Equity | \$9,700,000 | Seattle | 7/21/2020 | Curvafix | Equity | \$10,750,000 | Bellevue |
| 3/19/2020 | Concure Oncology | Equity | \$7,750,000 | Mercer Island | 7/22/2020 | Magnolia Neurosciences | Equity | \$5,000,000 | Seattle |
| 3/26/2020 | Novuson Surgical | Equity | \$2,380,000 | Bothell | 7/30/2020 | Intrinsic Medicine | Convertible Debt | undisclosed | Des Moines |
| 4/1/2020 | YouScript | M&A | \$52,700,000 | Seattle | 8/4/2020 | Proprio | Equity | \$220,000 | Seattle |
| 4/1/2020 | SCI Solutions | Equity | \$190,000,000 | Seattle | 8/6/2020 | Xealth | Equity | \$6,000,000 | Seattle |
| 4/1/2020 | Genelex | M&A | \$13,210,000 | Seattle | 8/10/2020 | Variant Bio | Equity | \$8,100,000 | Seattle |
| 4/2/2020 | Blaze Bioscience | Equity | \$23,230,000 | Seattle | 8/13/2020 | Aminex Therapeutics | Convertible Debt | \$2,870,000 | Newcastle |
| 4/2/2020 | Rodeo Therapeutics | Equity | \$8,950,000 | Seattle | 8/20/2020 | Optimize.health | Equity | \$15,000,000 | Seattle |
| 4/3/2020 | 98point6 | Equity | \$43,000,000 | Seattle | 8/25/2020 | Adyn | SAFE | \$150,000 | Seattle |
| 4/6/2020 | Juva for Migraine | Equity | \$500,000 | Clyde Hill | 8/25/2020 | Prescriptive | Equity | \$26,000,000 | Redmond |
| 4/15/2020 | SiDx | Convertible Debt | \$1,250,000 | Seattle | 8/27/2020 | Deverra Therapeutics | Equity | \$80,000 | Seattle |
| 4/15/2020 | Mindshare Medical | Equity | \$150,000 | Seattle | 9/1/2020 | ActX | Equity | undisclosed | Seattle |
| 4/21/2020 | welcomehomehealth.com | Equity | \$1,500,000 | Vancouver | 9/1/2020 | Kineta | Equity | \$150,001 | Seattle |
| 4/22/2020 | Myosana Therapeutics | Equity | \$1,000,000 | Seattle | 9/2/2020 | Opticyte | Debt | \$1,500,000 | Seattle |
| 4/24/2020 | Remmie | Equity | \$50,000 | Seattle | 9/1/2020 | Lumen Bioscience | Equity | \$16,000,000 | Seattle |
| 4/26/2020 | Avalyn | Equity | \$35,500,000 | Seattle | 9/11/2020 | AIDA Healthcare | Equity | \$1,550,000 | Kirkland |
| 4/30/2020 | OncoSenX | SAFE converted to Equity | \$4,140,000 | Seattle | 9/14/2020 | Implicit Bioscience | Equity | \$65,551 | Seattle |
| 5/1/2020 | Link Immunotherapeutics | Equity | undisclosed | Seattle | 9/17/2020 | Cyrus Biotechnology | Convertible Debt | \$1,130,000 | Seattle |
| 5/5/2020 | Kineta | Equity | \$7,950,000 | Seattle | 9/18/2020 | Athira Pharma | IPO | \$204,000,000 | Seattle |
| 5/7/2020 | Good (Drug Discovery) | Equity | \$22,340,000 | Seattle | 9/23/2020 | Silverback Therapeutics | Equity | \$85,000,000 | Seattle |
| | | | | | 9/25/2020 | Immusoft | Equity | \$4,500,000 | Seattle |
| | | | | | 9/25/2020 | Altpep | Equity | \$2,100,000 | Mercer Island |
| | | | | | 9/27/2020 | Inmedix | Debt and Equity | \$3,500,000 | Normandy Park |

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact laura@lswinstitute.org.

**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.



Washington Life Science Transactions

| <u>Date</u> | <u>Company</u> | <u>Type</u> | <u>Amount</u> | <u>Location</u> |
|--------------|-------------------------|------------------|------------------------|-----------------|
| 9/28/2020 | ImvaqTherapeutics | Equity | \$15,000,000 | Sammamish |
| 9/28/2020 | Cardiac Dimensions | Equity | \$17,500,000 | Kirkland |
| 9/29/2020 | TourniTek | Equity | \$10,265 | Seattle |
| 10/5/2020 | HDT Bio | Equity | \$3,000,000 | Seattle |
| 10/8/2020 | Wellzio | Equity | \$300,000 | Medina |
| 10/13/2020 | Genemod | Equity | \$1,700,000 | Seattle |
| 10/14/2020 | Hippo Technologies | Equity | \$100,750 | Seattle |
| 10/15/2020 | 98point6 | Equity | \$118,690,000 | Seattle |
| 10/15/2020 | AbSci | Equity | \$65,000,000 | Vancouver |
| 10/16/2020 | Freespira | Equity | \$10,000,000 | Kirkland |
| 10/20/2020 | DocToMe | Equity | \$2,170,000 | Gig Harbor |
| 10/28/2020 | Briotech | SAFE note | \$50,000 | Woodinville |
| 10/29/2020 | Concure Oncology | Equity | \$9,750,000 | Mercer Island |
| 11/10/2020 | Arzeda | Convertible Debt | \$4,250,000 | Seattle |
| 11/18/2020 | Umoja Biopharma | Equity | \$53,000,000 | Seattle |
| 11/29/2020 | Nextraction | Equity | 1,050,000 | Fife |
| 11/20/2020 | MicroMend | Convertible Debt | \$4,600,000 | Seattle |
| 12/4/2020 | Silverback Therapeutics | IPO | \$241,500,000 | Seattle |
| 12/7/2020 | EndoGastric Solutions | Equity | \$27,000,000 | Redmond |
| 12/16/2020 | Healionics | Equity | \$10,760,000 | Seattle |
| 12/21/2020 | LumiThera | Convertible Note | \$615,000 | Poulsbo |
| TOTAL | | | \$2,767,466,567 | |